| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -8,861 | -29,496 | -11,269 | 2,583 |
| Depreciation expense | 149 | 163 | 195 | 487 |
| Impairment of fixed assets | NaN | 7 | 1 | 82 |
| Loss on the sale and disposal of fixed assets | NaN | 33 | -328 | -11 |
| Non-cash stock compensation expense | 1,452 | 1,290 | 1,163 | 1,364 |
| Non-cash lease expense | 92 | 89 | 81 | 151 |
| Non-cash interest expense | 39 | 35 | 34 | 69 |
| Change in fair value of warrant liabilities | -7,643 | 13,519 | -1,146 | -20,572 |
| Accretion of debt discount | 306 | 263 | 21 | 76 |
| Prepaid expenses and other current assets | 1,260 | -1,202 | -61 | 1,771 |
| Other assets | 21 | 2 | 40 | -18 |
| Accounts payable | 1,698 | 33 | -744 | 1,513 |
| Accrued expenses | -3,858 | 2,289 | 1,208 | -1,243 |
| Deferred income | -22 | 178 | NaN | NaN |
| Lease liability | -108 | -105 | -129 | -275 |
| Net cash used in operating activities | -18,037 | -10,568 | -10,236 | -17,507 |
| Purchase of fixed assets | 675 | 409 | 144 | 34 |
| Proceeds from the sale of fixed assets | NaN | 0 | 27 | NaN |
| Proceeds from sale of common stock, net of issuance costs | NaN | NaN | 0 | 5,038 |
| Net cash used in investing activities | -675 | -409 | -117 | -34 |
| Principal payments on term loan payable to a bank | NaN | -4,233 | -2,500 | -5,000 |
| Proceeds from term loan, net of issuance costs | NaN | 47,946 | NaN | NaN |
| Proceeds from issuance of common stock in registered direct offering, net of issuance costs | NaN | 0 | -713 | 15,044 |
| Proceeds from sale of common stock through at-the-market offerings, net of issuance costs | NaN | 5,038 | NaN | NaN |
| Proceeds from option exercises | 28 | 4 | 20 | 492 |
| Payment of deferred debt issuance costs | NaN | NaN | 178 | NaN |
| Proceeds from issuance of common stock in public offering, net of issuance costs | 93,787 | NaN | NaN | NaN |
| Net cash provided by (used in) financing activities | 93,815 | 43,895 | -3,371 | 15,574 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 75,103 | 32,918 | -13,724 | -1,967 |
| Cash, cash equivalents and restricted cash at beginning of period | 120,147 | 87,229 | 102,920 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 195,250 | 120,147 | 87,229 | NaN |
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)